Affinity Discovers SARS-CoV-2 Antibodies

Demonstrate therapeutic potential to neutralize the infectivity of COVID-19.

By: Contract Pharma

Contract Pharma Staff

Affinity Biosciences Pty Ltd., a privately held company focused on antibody discovery for cancer therapeutics, has discovered potent antibodies with therapeutic potential against COVID-19.   In March, Affinity commenced screening its proprietary library of one hundred billion human antibodies to discover those that might neutralise SARS-CoV-2, the virus that causes COVID-19. After discovering a number of candidate antibodies that block the virus spike protein from binding to its human receptor, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters